FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

CDC recommends new MMVR vaccination strategy; Genital wart infections plunge after HPV vax campaign


Vaccine Market

One of the big advantages of Merck's MMRV vaccine was that it combined four childhood jabs into one. But new evidence that the shot increases the risk of febrile seizures in infants led to a new recommendation from the CDC that physicians deliver the vaccine in two steps rather than one. Story

The rate of genital wart infections has plunged in Australia, the result of a mass HPV vaccination program. Story

Vaccine Research

A new primate study indicates that people exposed to the lethal Marburg virus may be protected by a vaccination a day or two after exposure. Story

Novavax named Gregory Glenn, M.D., as the company's chief scientific officer. Glenn is credited with providing "the scientific and technical leadership that led to the acquisition of IOMAI by Intercell in 2008." He has co-authored more than 150 research publications, scientific abstracts and presentations, and successful grant applications. Release

Researchers in Australia are putting a new nasal drop vaccine through trials for respiratory syncytial virus (RSV) and the parainfluenza virus type 3 (PIV3) in infants and toddlers.  Story

The cancer vaccine developer Oncothyreon has gained commitments for up to $20 million in fresh financing. Report

James Connolly has been named president and CEO of the Aeras Global TB Vaccine Foundation. Release

Crucell and Sanofi Pasteur have restructured their agreement on vaccine development. Release

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.